The US Food and Drug Administration (FDA) has granted 510(k) clearance for Nephros’ hemodiafiltration (HDF) system, designed for the treatment of chronic kidney disease (CKD).

The hemodiafiltration system is used in conjugation with UF controlled dialysis machines capable of producing ultrapure dialysate to improve the quality of life for end-stage renal disease (ESRD) patients.

The HDF system features the company’s OLpur MD220 hemodiafilter that employs proprietary mid-dilution hemodiafiltration technology and the OLpur H2H hemodiafiltration module, which is intended for use with UF controlled dialysis machines.

The HDF system removes a range of harmful substances effectively and with greater capacity than existing ESRD treatment methods, particularly with respect to substances known collectively as middle molecules, the company said.

Leonard Stern, Columbia University College of Physician and Surgeons medicine associate clinical professor and Columbia University Dialysis Center medical director, said HDF represents an alternative treatment option for chronic renal failure and patients in the US will now have the opportunity to be treated with the important therapy.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nephros president and CEO, John Houghton, said the company can now offer the only on-line HDF therapy available in the US.

“Nephros will first pursue a limited launch of its HDF system before expanding into the broader market. In parallel, Nephros will evaluate opportunities to leverage the resources of a strategic partner to most effectively address the market,” Houghton added.

Nephros is a US-based medical device company focused on developing and marketing filtration products for therapeutic applications, infection control and water purification.

Image: The hemodiafiltration system from Nephros has been approved by the FDA. Photo courtesy of: FDA.